| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 202.7 | 205.7 |
| Gross profit | 137.7 | 143.8 |
| Profit before tax | -43.6 | -26.2 |
| Net income | -43.9 | -27.4 |
| EPS (diluted, $ a share) | $-0.46 | $-0.29 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -1.5% |
|---|---|
| Gross margin | 67.9% |
| Operating margin | -19.7% |
10-Q filed with the SEC, NASDAQ: MYGN. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Myriad Genetics Inc: key numbers
- Share price
- $5.57Close, Nov 16
- Market cap
- $534M
- Shares outstanding
- 95.92MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- In Vitro & In Vivo Diagnostic SubstancesSIC 2835
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Myriad Genetics Inc
All →Myriad Genetics Stock Plan Amendment
Myriad Genetics approved one-time retention stock option awards for its executive leadership team, including the CFO, COO, and CSO. The awards are granted under the 2026 Equity Incentive Plan and will vest fully on the third anniversary of the grant date to ensure leadership continuity during operational efficiency initiatives.
Myriad Genetics Cybersecurity Incident
Myriad Genetics detected unauthorized access to its IT network on November 2, 2026, leading to a temporary suspension of testing operations and order management systems. The company has engaged external experts to investigate the scope of the breach, including potential access to patient records, though most systems have since returned to normal operations. Management currently believes the incident will not have a material adverse effect on the business.
Myriad Genetics Earnings Call: Key Takeaways
The provided transcript contains no substantive financial data or management commentary, consisting only of repetitive noise characters.
- Call
- Nov 4, 2026, 4:30 PM ET
Myriad Genetics Financial Results
Myriad Genetics reported Q3 2026 revenue of $202.7 million and raised its full-year revenue guidance mid-point. The company also highlighted a definitive agreement to sell its Prenatal Health business to Labcorp for $210 million in cash to focus on its Cancer Care Continuum and Mental Health segments.
- Counterparty
- Labcorp
“We have made meaningful progress on our path to accelerate profitable growth and strengthen the company’s financial profile. Our third quarter 2026 financial results exceeded our expectations, led by our on-going focus on the Cancer Care Continuum (CCC).”
Sam Raha, President and CEO, Myriad Genetics
“The sale of our Prenatal Health business is a decisive step to support our strategic intent to increase profitable growth by focusing on the Cancer Care Continuum including screening, treatment selection and monitoring along with remission surveillance.”
Sam Raha, President and CEO, Myriad Genetics
Myriad Genetics Divestiture to Laboratory Corporation of America for $210M
Myriad Genetics has entered into a definitive agreement to sell its prenatal health testing business, including the Foresight, Prequel, and SneakPeek tests, to Labcorp for $210 million in cash. The divestiture is part of a strategic review to focus on the company's cancer care continuum and is expected to close by early 2027.
- Value
- $210M
- Counterparty
- Laboratory Corporation of America
Myriad Genetics Executive Compensation
Myriad Genetics entered into a separation agreement with former Chief Commercial Officer Brian Donnelly following his departure on September 21, 2026. Mr. Donnelly will receive a lump sum severance payment of approximately $1.32 million and accelerated vesting of outstanding time-based and performance-based equity awards for a two-year period. The agreement includes customary non-solicitation and non-disparagement covenants and a release of claims against the company.
- Counterparty
- Brian Donnelly